What is the Impact Factor of Leukemia & Lymphoma?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Leukemia & Lymphoma is 2.10, ranking in quartile Q3 of Web of Science (SCIE).

Is Leukemia & Lymphoma indexed in Web of Science or Scopus?

Yes, Leukemia & Lymphoma is indexed in Web of Science (SCIE, Q3 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 0.861 (Q2) and an H-index of 109.

Who publishes Leukemia & Lymphoma and what is the Article Processing Charge (APC)?

Leukemia & Lymphoma is published by Informa Healthcare. The estimated Article Processing Charge (APC) is approximately $3,196 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Leukemia & Lymphoma?

The official ISO-4 abbreviation of Leukemia & Lymphoma is "LEUKEMIA LYMPHOMA" with common acronym "glal". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q3Scopus Q2SCImago #6,182Hybrid

Leukemia & Lymphoma

Acronym:glal

•

Abbreviation (ISO):LEUKEMIA LYMPHOMA

•

Identifier (ISSN):1042-8194(Print)/1029-2403(Online)

•

Publisher:Informa Healthcare

Official Website Submission Portal Compare

Clarivate IF (2026)

2.1↓ -0.1

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIEJCR Quartile

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Leukemia & Lymphoma

WoS Q3

Annual Impact Factor Metric

Current (2026):2.1

Scopus SJR & RankScopus Q2

0.861

#6,182

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

109

109 papers with at least that number of citations each

WoS: SCIE / JCRQ3

Self-Citation Rate0%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

284articles/year

12.17% Gold OA•82.89% Original Research

Aims & Scope

Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor

Topics Covered (Recognized by AI)

Medicine99.6%Biology98.6%Internal medicine96.6%Immunology92.5%Genetics89.1%Pathology71.4%Chemistry53.6%Surgery48.5%Biochemistry48%Cancer research47.7%Oncology39.2%Lymphoma38.2%Leukemia37.5%Chemotherapy31.5%Gene28.3%Cell biology26.1%Gastroenterology21.5%Antibody20.9%

Primary Research Areas

Medicine Hematology

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

HEMATOLOGY

Rank61/103

IndexSCIE

JCRSCIE2026

ONCOLOGY

Rank236/333

IndexSCIE

JCISCIE2026

HEMATOLOGY

Rank67/103

IndexSCIE

JCISCIE2026

ONCOLOGY

Rank249/333

IndexSCIE

Category	Index	Rank	Quartile
HEMATOLOGY	JCRSCIE	61/103	Q3
ONCOLOGY	JCRSCIE	236/333	Q3
HEMATOLOGY	JCISCIE	67/103	Q3
ONCOLOGY	JCISCIE	249/333	Q3

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF2.1

Articles / Year232

Total Citations49

2025

IF2.2

Articles / Year349

Total Citations414

2024

IF2.2

Articles / Year334

Total Citations1,082

2023

IF2.6

Articles / Year285

Total Citations1,240

2022

IF2.996

Articles / Year414

Total Citations2,595

Year	Impact Factor	Articles / Year	Total Citations
2026	2.1	232	49
2025	2.2	349	414
2024	2.2	334	1,082
2023	2.6	285	1,240
2022	2.996	414	2,595
2021	3.28	465	4,000
2020	2.969	542	5,361
2019	2.674	501	6,242
2018	2.644	350	4,803
2017	—	475	7,722
2016	—	531	8,333
2015	—	460	7,765

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #6,182Scopus Q2SCImago Profile

Scopus Coverage:1989-2026

•

Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicine

Scopus Citation Rank (SJR)Q2

0.861

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2

Citations / Doc (2 years)

1.64

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,196 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,720

3-Year Documents1,072

Citable Documents679

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)1

Citations in government and international policy documents

Female Author Rate44.5%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

HematologyQ2

OncologyQ2

Cancer ResearchQ3

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 0%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

4区 (Zone 4)Medicine

Minor Category (Specific Field):

4区ONCOLOGY

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Leukemia & Lymphoma (acronym: glal, abbr: LEUKEMIA LYMPHOMA, ISSN: 1042-8194) is a peer-reviewed international scholarly journal in the field of Medicine, published by Informa Healthcare in England since 1989. The periodical holds a Journal Impact Factor (JIF) of 2.10, ranking in quartile Q3 of Web of Science (SCIE), a Scopus SJR indicator of 0.861 (Q2), an H-index of 109.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 284 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,196 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.